- Home
- BCTXW
as 11-14-2024 3:31pm EST
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
| Founded: | N/A | Country: | Canada |
| Employees: | 18 | City: | WEST VANCOUVER |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BriaCell Therapeutics Corp. Warrant News
BCTXW Breaking Stock News: Dive into BCTXW Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
GlobeNewswire
11 days ago
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
MT Newswires
24 days ago
BriaCell Higher as it Reports "Standard-Beating" Survival Data From Phase 2 Study
GlobeNewswire
24 days ago
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
MT Newswires
a month ago
BriaCell to Complete Patient Enrollment for Phase 3 Breast Cancer Study by Mid-2025; Shares Rise
GlobeNewswire
a month ago
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
MT Newswires
a month ago
BriaCell Therapeutics Closes Offering of 5.13 Million Shares, Warrants
GlobeNewswire
a month ago
BriaCell Therapeutics Announces Closing of $5 Million Offering
Compare BCTXW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCTXW BriaCell Therapeutics Corp. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.